The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 2 open-label study of pembrolizumab plus lenvatinib and belzutifan in patients with advanced solid tumors.
 
Robin Kate Kelley
Consulting or Advisory Role - Agios (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Exact Sciences; Exelixis/Ipsen (Inst); Genentech/Roche; Gilead Sciences; Kinnate Biopharma; Merck (Inst)
Research Funding - Adaptimmune (Inst); Agios (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Exelixis (Inst); Genentech/Roche (Inst); Lilly (Inst); Loxo/Lilly (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Partner Therapeutics (Inst); QED Therapeutics (Inst); Relay Therapeutics (Inst); Surface Oncology (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Ipsen
 
Eric Van Cutsem
Consulting or Advisory Role - Array BioPharma; Astellas Pharma; AstraZeneca; Bayer; Biocartis; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; GlaxoSmithKline; Halozyme; Incyte; Lilly; Merck KGaA; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche; SERVIER; Sirtex Medical; Taiho Pharmaceutical
Research Funding - amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Merck KGaA (Inst); Novartis (Inst); Roche (Inst); SERVIER (Inst)
 
Michael Sangmin Lee
Consulting or Advisory Role - Pfizer
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); EMD Serono; Exelixis (Inst); Genentech/Roche; Pfizer (Inst); Rafael Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Genentech/Roche
 
Ido Wolf
Consulting or Advisory Role - Novartis
Speakers' Bureau - Novartis
Research Funding - Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb (Mexico) (Inst)
 
Marwan Fakih
Honoraria - Amgen
Consulting or Advisory Role - Amgen; Array BioPharma; Bayer; GlaxoSmithKline; Incyte; Pfizer; Seagen; Taiho Pharmaceutical; Zhuhai DL Biotech
Speakers' Bureau - Guardant Health
Research Funding - Amgen (Inst); AstraZeneca (Inst); Novartis (Inst)
 
Judith de de Vos-Geelen
Consulting or Advisory Role - Amgen; AstraZeneca; MSD; Pierre Fabre; SERVIER
Research Funding - SERVIER (Inst)
Travel, Accommodations, Expenses - SERVIER
 
Valerie Lee
Research Funding - Merck; Novartis
 
Arndt Vogel
Honoraria - Advanced Accelerator Applications/Imaging Equipment Ltd; Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; Daichi-Sankyo; Incyte; Ipsen; Janssen; Lilly; MSD; Pierre Fabre; Roche; Sanofi; Sirtex Medical; TERUMO; TERUMO
Consulting or Advisory Role - Amgen; AstraZeneca; Baxalta; Bayer; BTG; Daichi-Sankyo; Eisai; IPSEN; Lilly; Novartis; Pierre Fabre; Roche; Sirtex Medical; Terumo
Research Funding - Novartis
Travel, Accommodations, Expenses - AstraZeneca; Ipsen; Roche
 
Larry Wu
Employment - Merck
 
Fan Jin
Employment - Merck
Stock and Other Ownership Interests - Merck
Travel, Accommodations, Expenses - Merck
 
Girish S. Naik
Employment - Leap Therapeutics; Merck
Stock and Other Ownership Interests - Leap Therapeutics; Merck; Tonix Pharmaceuticals; Vaxart; Zomedica
Patents, Royalties, Other Intellectual Property - Leap Therapeutics
Travel, Accommodations, Expenses - Merck
 
Eileen Mary O'Reilly
Consulting or Advisory Role - Adicet Bio (I); Alnylam (I); AstraZeneca (I); Autem Medical (I); BeiGene (I); Berry Genomics (I); BioSapien; BioSapien; Boehringer Ingelheim; Cend Therapeutics; CytomX Therapeutics; CytomX Therapeutics; Eisai (I); Exelixis (I); Flatiron Health (I); Genentech/Roche (I); Genoscience Pharma (I); Helio Health (I); IDEAYA Biosciences; Incyte (I); Ipsen (I); Legend Biotech (I); Merck; Nerviano Medical Sciences (I); Novartis; Noxxon Pharma; QED Therapeutics (I); Rafael Pharmaceuticals; RedHill Biopharma (I); Seagen; Thetis Pharma; Yiviva (I)
Research Funding - Arcus Ventures (Inst); AstraZeneca/MedImmune (Inst); BioNTech (Inst); Celgene (Inst); Elicio Therapeutics (Inst); Genentech (Inst); Parker Institute for Cancer Immunotherapy (Inst); Roche (Inst); Silenseed (Inst)